Yuan Run-Qiang
Department of Urology, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, China.
Zhonghua Nan Ke Xue. 2012 Dec;18(12):1147-51.
Tadalafil, as a selective phosphodiesterase type 5 inhibitor (PDE5I), has revolutionized the treatment of erectile dysfunction (ED) in men. Conventional management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), which is highly complex and likely multifactorial, is associated with unwanted side effects. Innovative once-daily tadalafil regimen is effective in treating the signs and symptoms of BPH. In recent trials in men with BPH, tadalafil significantly improved total IPSS over the initial 12 weeks of medication. Moreover, tadalafil is effective in treating both ED and the signs and symptoms of BPH. In this study, we review the current state of this new management strategy for LUTS secondary to BPH, highlighting the published reports on the efficacy and tolerability of tadalafil.
他达拉非作为一种选择性5型磷酸二酯酶抑制剂（PDE5I），彻底改变了男性勃起功能障碍（ED）的治疗方法。良性前列腺增生（BPH）继发的下尿路症状（LUTS）的传统管理非常复杂且可能是多因素的，会产生不良副作用。创新的他达拉非每日一次给药方案对治疗BPH的体征和症状有效。在最近针对BPH男性的试验中，他达拉非在用药的最初12周内显著改善了总国际前列腺症状评分（IPSS）。此外，他达拉非对治疗ED以及BPH的体征和症状均有效。在本研究中，我们回顾了这种针对BPH继发LUTS的新管理策略的现状，重点介绍了关于他达拉非疗效和耐受性的已发表报告。
